Treasuries have been witnessing strong momentum in recent weeks, buoyed by Fed rate cut speculations. The latest inflation data signals confirmed bets that the Fed will cut rates next week, pushing up...
ETFs across various categories pulled in $7.1 billion in capital last week, pushing the year-to-date inflows to $605.5 billion. U.S. fixed-income ETFs led the way with $9.4 billion in inflows, followed...
The U.S. job market may have been significantly weaker over the past year than previously believed, as the Bureau of Labor Statistics (BLS) has indicated a potential downward revision of payroll numbers...
Another Federal Reserve Board meeting has left the Fed Funds rate unchanged at 5.25 to 5.50%. Due to the stickiness of inflation being higher than their 2% target, they have reduced the chances of rate...
Are you looking to buy a new home or refinance at a lower rate? The media is talking about rates being higher for longer. And they are correct about short-term rates that don't impact mortgages as much...
Earlier this month, Goldman Sachs’ head of asset allocation research opined that bonds are becoming ...
Traditionally reliable, the 60/40 portfolio may no longer guarantee solid returns amid concerns about rising interest rates and rising bond yields.
The Fed's July meeting starts today and most traders expect a 25-basis point rate hike. Could Fed Chair Jerome Powell play the rally-killer yet again, or give traders more reasons to buy?
T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment.